Regulation, Reimbursement Notes From Turkey
This article was originally published in PharmAsia News
Executive Summary
A PharmAsia News update shows Turkey has set a target to domestically manufacture 60% of the drug products used annually and 20% of medical device and equipment by an unspecified timeframe. The government also moved to offer more support into R&D for high-value biopharmaceutical products and sent a large ministerial delegation to the annual Bio Conference in San Diego as a signal of how important the sector is to its public health programs.
You may also be interested in...
BIO 2014 Monday Round-Up: Let’s Make A Deal
The annual BIO conference opened in San Diego with deals being announced at the outset and everyone enthusiastic about partnering.
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
A Bright Moment At Last In Turkish Medtech Debt Payments Saga
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.